TR
TRAX
First Tracks Biotherapeutics, Inc.
$17.64
+3.58%
$615.5M
No data for this timeframe.
Vol
Market Cap$615.5M
Cap SizeSmall Cap
Insider Activity0B / 1S
Insider Net $-$65.0M
SEC Reports11
Recent Activity
May 14, 2026
SEC
First Tracks Biotherapeutics reported a net loss of $50.5M for Q1 2026, wider than the $47.2M loss in Q1 2025, as a clin
8-K — Impact 4/10
May 13, 2026
SEC
First Tracks Biotherapeutics' S-1 registration (333-295719) became effective on May 12, 2026, covering the resale of up
EFFECT — Impact 4/10
May 12, 2026
Insider
Jain Rita was granted 7,000 shares
Director
May 12, 2026
Insider
Jain Rita was granted 2,500 shares
Director
May 12, 2026
Insider
Schmid John P. was granted 7,000 shares
Director
May 8, 2026
SEC
First Tracks Biotherapeutics filed an S-1 registration statement for the resale of up to 10,497,054 shares of common sto
S-1 — Impact 2/10
Apr 23, 2026
short_interest
FTD: TRAX — 31,496 shares ($0.6M) failed to deliver
Settlement: 20260423, Price: $18.87, FTD Value: $594,329.52, FIRST TRACKS BIOTHERAPEUTICS I
Price Targets
No recent covering-analyst activity on file. No current recommendation available.
$38.13
Current $17.64
Low $30.00
Median $35.00
High $54.00
8 analysts
$30.00
$54.00
Analyst Ratings
4Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.81 ▼ -53.6% | $-1.01 — $-0.62 | 8 | |
| Next Q | $-0.79 ▼ -2.6% | $-0.91 — $-0.62 | 8 | |
| Current FY | $-3.60 ▼ -35.0% | $-4.17 — $-3.30 | 8 | |
| Next FY | $-3.14 ▲ +4.1% | $-4.13 — $-2.28 | 13% YoY | 8 |
Latest Reports
NEUTRAL
8-K
4/10
First Tracks Biotherapeutics reported a net loss of $50.5M for Q1 2026, wider than the $47.2M loss in Q1 2025, as a clin
May 14, 2026
NEUTRAL
EFFECT
4/10
First Tracks Biotherapeutics' S-1 registration (333-295719) became effective on May 12, 2026, covering the resale of up
May 13, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 12, 2026 | Jain Rita | A | $0.00 |
| May 12, 2026 | Jain Rita | A | $0.00 |
| May 12, 2026 | Schmid John | A | $0.00 |
| May 12, 2026 | Schmid John | A | $0.00 |
| May 12, 2026 | Orwin John | A | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
12 unique insiders with 50 transactions. Net insider value: -$65.0M ($0.00 bought, $65.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 12, 2026 | Jain Rita | Director | AWARD | 7,000 | — | — |
| May 12, 2026 | Jain Rita | Director | AWARD | 2,500 | — | — |
| May 12, 2026 | Schmid John P. | Director | AWARD | 7,000 | — | — |
| May 12, 2026 | Schmid John P. | Director | AWARD | 2,500 | — | — |
| May 12, 2026 | Orwin John A | Director | AWARD | 7,000 | — | — |
| May 12, 2026 | Orwin John A | Director | AWARD | 2,500 | — | — |
| May 12, 2026 | Marquet Magda | Director | AWARD | 7,000 | — | — |
| May 12, 2026 | Marquet Magda | Director | AWARD | 2,500 | — | — |
| May 12, 2026 | Tamboli Ajim | Chief Financial Officer | AWARD | 5,000 | — | — |
| May 12, 2026 | Tamboli Ajim | Chief Financial Officer | AWARD | 13,600 | — | — |
| May 12, 2026 | Lizzul Paul F. | Chief Medical Officer | AWARD | 26,700 | — | — |
| May 12, 2026 | Lizzul Paul F. | Chief Medical Officer | AWARD | 72,300 | — | — |
| May 12, 2026 | Orwin John A | Director | AWARD | 15,000 | — | — |
| May 12, 2026 | Orwin John A | Director | AWARD | 42,000 | — | — |
| May 12, 2026 | FENTON DENNIS M | Director | AWARD | 15,000 | — | — |
| May 12, 2026 | FENTON DENNIS M | Director | AWARD | 42,000 | — | — |
| May 12, 2026 | STONE BENJAMIN | Chief Business Officer | AWARD | 72,300 | — | — |
| May 12, 2026 | Ware J. Anthony | Director | AWARD | 15,000 | — | — |
| May 12, 2026 | Faga Daniel | President, CEO | AWARD | 100,200 | — | — |
| May 12, 2026 | Faga Daniel | President, CEO | AWARD | 271,100 | — | — |
| May 12, 2026 | Marquet Magda | Director | AWARD | 15,000 | — | — |
| May 12, 2026 | STONE BENJAMIN | Chief Business Officer | AWARD | 26,700 | — | — |
| May 12, 2026 | Marquet Magda | Director | AWARD | 42,000 | — | — |
| May 12, 2026 | Ware J. Anthony | Director | AWARD | 42,000 | — | — |
| May 12, 2026 | Jain Rita | Director | AWARD | 15,000 | — | — |
| May 12, 2026 | Jain Rita | Director | AWARD | 42,000 | — | — |
| May 12, 2026 | Schmid John P. | Director | AWARD | 15,000 | — | — |
| May 12, 2026 | Schmid John P. | Director | AWARD | 42,000 | — | — |
| Apr 23, 2026 | Tamboli Ajim | Chief Financial Officer | AWARD | 41,234 | — | — |
| Apr 22, 2026 | Tamboli Ajim | Chief Financial Officer | AWARD | 41,233 | — | — |
| Apr 21, 2026 | Tamboli Ajim | Chief Financial Officer | AWARD | 45,700 | — | — |
| Apr 21, 2026 | Tamboli Ajim | Chief Financial Officer | AWARD | 41,233 | — | — |
| Apr 20, 2026 | Faga Daniel | President, CEO | AWARD | 17,850 | — | — |
| Apr 20, 2026 | Jain Rita | Director | AWARD | 10,600 | — | — |
| Apr 20, 2026 | ANAPTYSBIO, INC | 10%+ Owner | J | 100 | — | — |
| Apr 20, 2026 | Orwin John A | Director | AWARD | 3,311 | — | — |
| Apr 20, 2026 | Orwin John A | Director | AWARD | 1,300 | — | — |
| Apr 20, 2026 | Marquet Magda | Director | AWARD | 784 | — | — |
| Apr 20, 2026 | Schmid John P. | Director | AWARD | 6,030 | — | — |
| Apr 20, 2026 | FENTON DENNIS M | Director | AWARD | 6,000 | — | — |
| Apr 20, 2026 | FENTON DENNIS M | Director | AWARD | 6,030 | — | — |
| Apr 20, 2026 | Jain Rita | Director | AWARD | 1,300 | — | — |
| Apr 20, 2026 | Faga Daniel | President, CEO | AWARD | 11,000 | — | — |
| Apr 20, 2026 | Schmid John P. | Director | AWARD | 15,000 | — | — |
| Apr 20, 2026 | Marquet Magda | Director | AWARD | 6,030 | — | — |
| Apr 20, 2026 | Lizzul Paul F. | Chief Medical Officer | AWARD | 83,500 | — | — |
| Apr 20, 2026 | Lizzul Paul F. | Chief Medical Officer | AWARD | 6,145 | — | — |
| Apr 20, 2026 | Ware J. Anthony | Director | AWARD | 6,030 | — | — |
| Apr 20, 2026 | Ware J. Anthony | Director | AWARD | 28,571 | — | — |
| Apr 20, 2026 | EcoR1 Capital, LLC | 10%+ Owner | SELL | 4,705,575 | $13.81 | $65.0M |
11 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 11 neutral. Avg impact: 2.8/10.
NEUTRAL
8-K
4/10
First Tracks Biotherapeutics reported a net loss of $50.5M for Q1 2026, wider than the $47.2M loss i
May 14, 2026
NEUTRAL
EFFECT
4/10
First Tracks Biotherapeutics' S-1 registration (333-295719) became effective on May 12, 2026, coveri
May 13, 2026
NEUTRAL
S-1
2/10
First Tracks Biotherapeutics filed an S-1 registration statement for the resale of up to 10,497,054
May 8, 2026
NEUTRAL
3
3/10
Rita Jain filed a Form 3 disclosing her initial beneficial ownership of securities in First Tracks B
Apr 1, 2026
NEUTRAL
3
2/10
Ware J. Anthony filed a Form 3 disclosing initial beneficial ownership of securities in First Tracks
Apr 1, 2026
NEUTRAL
3
2/10
John P. Schmid filed a Form 3 disclosing initial beneficial ownership of securities in First Tracks
Apr 1, 2026
NEUTRAL
3
2/10
Dennis M. Fenton filed a Form 3 indicating initial beneficial ownership of securities in First Track
Apr 1, 2026
NEUTRAL
3
3/10
Marquet Magda, affiliated with ALTHEADX INC., filed a Form 3 disclosing initial beneficial ownership
Apr 1, 2026
NEUTRAL
3
3/10
Two Form 3 filings were submitted for First Tracks Biotherapeutics, Inc. (TRAX) on April 1, 2026, di
Apr 1, 2026
NEUTRAL
3
2/10
Daniel Faga, President and CEO of First Tracks Biotherapeutics, Inc., filed a Form 3 to report his i
Apr 1, 2026
NEUTRAL
3
4/10
AnaptysBio, Inc. has spun off First Tracks Biotherapeutics, Inc. as a separate entity, with AnaptysB
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 92% buy across 12 analysts — 4 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
No recent covering-analyst activity on file. No current recommendation available.
$38.13 mean target
$30.00 Low
$54.00 High
| Metric | Value |
|---|---|
| Current Price | $17.64 |
| Target Low | $30.00 |
| Target Mean | $38.13 |
| Target Median | $35.00 |
| Target High | $54.00 |
| # Analysts | 8 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.81 | $-1.01 | $-0.62 | — | -53.6% | 1↑ 0↓ | $0.0B | — | 8 |
| Next Q 2026-09-30 |
$-0.79 | $-0.91 | $-0.62 | — | -2.6% | 1↑ 0↓ | $0.0B | — | 8 |
| Current FY 2026-12-31 |
$-3.60 | $-4.17 | $-3.30 | — | -35.0% | 0↑ 1↓ | $0.0B | — | 8 |
| Next FY 2027-12-31 |
$-3.14 | $-4.13 | $-2.28 | 12.9% | +4.1% | 1↑ 0↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.808 | |
| 7d ago | $-0.810 | +0.003 |
| 30d ago | $-0.526 | -0.282 |
| 60d ago | $0.000 | -0.808 |
| 90d ago | $0.000 | -0.808 |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 23, 2026
short_interest
FTD: TRAX — 31,496 shares ($0.6M) failed to deliver
Settlement: 20260423, Price: $18.87, FTD Value: $594,329.52, FIRST TRACKS BIOTHERAPEUTICS I
Apr 21, 2026
short_interest
FTD: TRAX — 213,031 shares ($4.0M) failed to deliver
Settlement: 20260421, Price: $18.60, FTD Value: $3,962,376.6, FIRST TRACKS BIOTHERAPEUTICS I
Apr 20, 2026
other
First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
<p>SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) today announced its launch as an independent, pub